Released Aug 5, 2024, after the close
10-Q filed Aug 5, 2024, 36 days after period end · 0000950170-24-090782
Q2 2024 · 10-Q
Revenue$114.00K$114.00K −57.6% vs Q2 2023−18.6% vs Q1 2024
Net Income-$17.86M-$17.86M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.33-$0.33 N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$19,061,000N/M
Operating Cash Flowderived-$18,744,000N/M
Margins · derived
Operating margin-16720.2%−11928.4 pt vs Q2 2023
Net margin-15668.4%−11244.6 pt vs Q2 2023
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $114.00K | $269.00K | $896.00K | $2.11M |
| Net Income | -$17.86M | -$11.90M | -$28.70M | -$18.60M |
| EPS Diluted | -$0.33 | -$0.23 | -$0.87 | -$0.63 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR